Reports
Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
Sale
Global Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market: By Product: Bronchodilators, Oxygen Therapy, Augmentation Therapy, Corticosteroids; By Route of Administration; By Application; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics; Competitive Landscape; Industry Events and Developments
Global Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Outlook
The global Alpha-1 Antitrypsin Deficiency (AATD) Treatment market is expected to grow at a CAGR of 9.5% during the period 2022-2027. The prevalence is nearly 0.025% in general population. Asia has comparatively less incidence of AATD as compared to Europe or North American population. North America and Europe are likely to be key markets.
Global Market Likely to be Driven by Advantages Offered by the Need to Effectively Treat Alpha-1 antitrypsin deficiency (AATD)
Alpha-1 antitrypsin deficiency (AATD) is a genetic illness, and may cause severe lung or liver disease. Symptoms may include trouble breathing and jaundiced, or yellow, skin.
Complications of Alpha-1 antitrypsin deficiency (AATD) depend on the disease it causes. These may include: lungs [if lung disease is developed, complications may include emphysema or bronchiectasis (damage to airway walls in the lungs)], liver (if liver disease is causes, symptoms may include swelling of abdomen and legs, higher risk of infections, or developing liver scarring or cancer), skin (in rare cases, a skin disease called panniculitis may develop; the condition may cause painful red lumps on the skin; the lumps may break open and release liquid or pus).
Augmentation therapy is the only particular therapy for alpha-1 antitrypsin deficiency (AATD); during the therapy, preparations of alpha-1 antitrypsin protein isolated from pooled blood of healthy donors are administered by way of weekly intravenous infusion. This raises the blood levels of alpha-1 antitrypsin deficiency AATD to levels protective for the lung. Studies report that augmentation therapy helps preserve lung function and reduces the number and severity of lung infections. While there is no cure for alpha-1 antitrypsin deficiency (AATD), the lung diseases that it causes can be treated. Treatment includes bronchodilators (enable easier breathing by relaxing the muscles surrounding the airways; short-acting bronchodilators last about four to six hours and are used as required; long-acting bronchodilators last twelve hours or more and may be used every day), inhaled corticosteroid medications (help decrease inflammation of the airways, enabling easy breathing), antibiotics, flu and pneumococcal vaccines, and surgery and other treatments (in advanced cases of disease, surgical options may be considered, such as lung volume reduction surgery and bullectomy). Along with treatment and medication, lifestyle changes may also be recommended, including exercise, training in managing the condition, and nutritional and psychological counselling.
Market Segmentation
By product, the market is segmented into:
- Bronchodilators
- Oxygen Therapy
- Augmentation Therapy
- Corticosteroids
By route of administration, the market is classified into:
- Injection
- Oral
- Inhalation
By application, the market is divided into:
- Specialty Clinics
- Hospitals
- Pharmacies
By region, the market is segmented into:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Key Industry Players in the Market
The report presents a detailed analysis of the following key players in the global Alpha-1 Antitrypsin Deficiency (AATD) Treatment market, looking into their capacity, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- Grifols, S.A.
- CSL Behring
- Takeda Pharmaceutical Company Limited
- Kamada Ltd
- Arrowhead Pharmaceuticals, Inc.
- Others
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2021 |
| Historical Period | 2017-2021 |
| Forecast Period | 2022-2027 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product |
|
| Breakup by Route of Administration |
|
| Breakup by Application |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*We at Expert Market Research always strive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Market Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Analysis
8.1 Key Industry Highlights
8.2 Global Alpha-1 Antitrypsin Deficiency (AATD) Treatment Historical Market (2017-2021)
8.3 Global Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Forecast (2022-2027)
8.4 Global Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market by Product
8.4.1 Bronchodilators
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2017-2021)
8.4.1.3 Forecast Trend (2022-2027)
8.4.2 Oxygen Therapy
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2017-2021)
8.4.2.3 Forecast Trend (2022-2027)
8.4.3 Augmentation Therapy
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2017-2021)
8.4.3.3 Forecast Trend (2022-2027)
8.4.4 Corticosteroids
8.4.4.1 Market Share
8.4.4.2 Historical Trend (2017-2021)
8.4.4.3 Forecast Trend (2022-2027)
8.5 Global Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market by Route of Administration
8.5.1 Injection
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2017-2021)
8.5.1.3 Forecast Trend (2022-2027)
8.5.2 Oral
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2017-2021)
8.5.2.3 Forecast Trend (2022-2027)
8.5.3 Inhalation
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2017-2021)
8.5.3.3 Forecast Trend (2022-2027)
8.6 Global Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market by Application
8.6.1 Specialty Clinics
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2017-2021)
8.6.1.3 Forecast Trend (2022-2027)
8.6.2 Hospitals
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2017-2021)
8.6.2.3 Forecast Trend (2022-2027)
8.6.3 Pharmacies
8.6.3.1 Market Share
8.6.3.2 Historical Trend (2017-2021)
8.6.3.3 Forecast Trend (2022-2027)
8.7 Global Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market by Region
8.7.1 Market Share
8.7.1.1 North America
8.7.1.2 Europe
8.7.1.3 Asia Pacific
8.7.1.4 Latin America
8.7.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2017-2021)
9.1.2 Forecast Trend (2022-2027)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2017-2021)
9.2.2 Forecast Trend (2022-2027)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2017-2021)
9.3.2 Forecast Trend (2022-2027)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2017-2021)
9.4.2 Forecast Trend (2022-2027)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2017-2021)
9.5.2 Forecast Trend (2022-2027)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Value Chain Analysis
12 Competitive Landscape
12.1 Market Structure
12.2 Company Profiles
12.2.1 Grifols, S.A.
12.2.1.1 Company Overview
12.2.1.2 Product Portfolio
12.2.1.3 Demographic Reach and Achievements
12.2.1.4 Certifications
12.2.2 CSL Behring
12.2.2.1 Company Overview
12.2.2.2 Product Portfolio
12.2.2.3 Demographic Reach and Achievements
12.2.2.4 Certifications
12.2.3 Takeda Pharmaceutical Company Limited
12.2.3.1 Company Overview
12.2.3.2 Product Portfolio
12.2.3.3 Demographic Reach and Achievements
12.2.3.4 Certifications
12.2.4 Kamada Ltd
12.2.4.1 Company Overview
12.2.4.2 Product Portfolio
12.2.4.3 Demographic Reach and Achievements
12.2.4.4 Certifications
12.2.5 Arrowhead Pharmaceuticals, Inc.
12.2.5.1 Company Overview
12.2.5.2 Product Portfolio
12.2.5.3 Demographic Reach and Achievements
12.2.5.4 Certifications
12.2.6 Others
13 Industry Events and Developments
List of Key Figures and Tables
1. Global Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market: Key Industry Highlights, 2017 and 2021
2. Global Alpha-1 Antitrypsin Deficiency (AATD) Treatment Historical Market: Breakup by Product (USD Million), 2017-2021
3. Global Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Forecast: Breakup by Product (USD Million), 2022-2027
4. Global Alpha-1 Antitrypsin Deficiency (AATD) Treatment Historical Market: Breakup by Route of Administration (USD Million), 2017-2021
5. Global Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Forecast: Breakup by Route of Administration (USD Million), 2022-2027
6. Global Alpha-1 Antitrypsin Deficiency (AATD) Treatment Historical Market: Breakup by Application (USD Million), 2017-2021
7. Global Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Forecast: Breakup by Application (USD Million), 2022-2027
8. Global Alpha-1 Antitrypsin Deficiency (AATD) Treatment Historical Market: Breakup by Region (USD Million), 2017-2021
9. Global Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Forecast: Breakup by Region (USD Million), 2022-2027
10. North America Alpha-1 Antitrypsin Deficiency (AATD) Treatment Historical Market: Breakup by Country (USD Million), 2017-2021
11. North America Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Forecast: Breakup by Country (USD Million), 2022-2027
12. Europe Alpha-1 Antitrypsin Deficiency (AATD) Treatment Historical Market: Breakup by Country (USD Million), 2017-2021
13. Europe Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Forecast: Breakup by Country (USD Million), 2022-2027
14. Asia Pacific Alpha-1 Antitrypsin Deficiency (AATD) Treatment Historical Market: Breakup by Country (USD Million), 2017-2021
15. Asia Pacific Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Forecast: Breakup by Country (USD Million), 2022-2027
16. Latin America Alpha-1 Antitrypsin Deficiency (AATD) Treatment Historical Market: Breakup by Country (USD Million), 2017-2021
17. Latin America Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Forecast: Breakup by Country (USD Million), 2022-2027
18. Middle East and Africa Alpha-1 Antitrypsin Deficiency (AATD) Treatment Historical Market: Breakup by Country (USD Million), 2017-2021
19. Middle East and Africa Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Forecast: Breakup by Country (USD Million), 2022-2027
20. Global Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Structure
Key Questions Answered in the Report
An increased chance of developing chronic obstructive pulmonary disease (COPD), liver disease, skin issues (panniculitis), and blood vessel inflammation is associated with alpha-1 antitrypsin deficiency (AATD), a hereditary condition (vasculitis).
Most people could live good life with normal life expectancies, work, enjoy sports, and exercise with the right care. Damage to the liver and lungs might have symptoms and problems that can be treated medically.
The market is projected to grow at a CAGR of 9.5% between 2022 and 2027.
The major drivers of the market include the growing number of strategic collaboration, research and development activities, rising number of genetic tests, blood tests, and biopsy tests, rising initiatives by public and private organisations, and an increase in the prescription for combination therapies.
Growing geriatric population and rising healthcare expenditure are the key industry trends propelling the market's growth.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The various products in the market are bronchodilators, oxygen therapy, augmentation therapy, and corticosteroids.
Based on route of administration, the market is classified into injection, oral, and inhalation.
The major applications of the market are speciality clinics, hospitals, and pharmacies.
Although there's no cure for AAT deficiency, but one can raise the amount of AAT protein in their blood, which protects the person against more lung damage. Doctors call this augmentation therapy.
The major players in the global Alpha-1 Antitrypsin Deficiency (AATD) treatment industry are Grifols, S.A., CSL Behring, Takeda Pharmaceutical Company Limited, Kamada Ltd, and Arrowhead Pharmaceuticals, Inc., among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 2199
$1799
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$3199$2999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$4199$3999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$5199$4999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER